Sana Biotechnology, Inc. (SANA) 8-K Current Report: March 3, 2026
Filed: March 3, 2026
Health Care
Biological Products, (No Diagnostic Substances)Sana Biotechnology, Inc. (SANA) 8-K current report filed with SEC EDGAR on March 3, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 2.02: Results of Operations and Financial Condition
- Item 8.01: Other Events
Sana Biotechnology, Inc. 8-K Mar 3, 2026 Event Analysis
Item 2.02 · Results of Operations and Financial Condition
- • Q4 and full-year 2025 financial results announced March 3, 2026
- • Actual figures in Exhibit 99.1 press release — key metrics not disclosed in this filing item
Item 8.01 · Other Events
- • ATM offering expanded: new S-3 filed for up to $150M in common stock sales via TD Cowen as agent
- • Prior ATM (May 2025) sold ~11.3M shares for ~$45.8M net proceeds; ~$71.6M of prior capacity unused but now superseded
- • TD Cowen compensation capped at 3.0% of gross proceeds; company retains full discretion on timing, size, and minimum price
- • Significant dilution risk: $150M at current prices represents material share count increase for existing holders
- • Company can suspend or terminate sales at any time — actual draw may be well below $150M ceiling depending on cash needs
Get deeper insights on Sana Biotechnology, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.